These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Network analysis of an in vitro model of androgen-resistance in prostate cancer. Detchokul S; Elangovan A; Crampin EJ; Davis MJ; Frauman AG BMC Cancer; 2015 Nov; 15():883. PubMed ID: 26553226 [TBL] [Abstract][Full Text] [Related]
26. miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence. Jiao L; Deng Z; Xu C; Yu Y; Li Y; Yang C; Chen J; Liu Z; Huang G; Li LC; Sun Y J Cell Physiol; 2014 Jul; 229(7):834-44. PubMed ID: 24243035 [TBL] [Abstract][Full Text] [Related]
27. [Interaction of WAVE1 and genes involved in multiple drug resistance in children with acute myeloblastic leukemia]. Yang MH; Zhao MY; He YL; Wang MH; Wang Z; Xie M; Wu XS; Cao LZ Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):175-9. PubMed ID: 20426950 [TBL] [Abstract][Full Text] [Related]
28. Leading causes of castration-resistant prostate cancer. Lu M; Lu H; Kong Q Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203 [TBL] [Abstract][Full Text] [Related]
29. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel. Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598 [TBL] [Abstract][Full Text] [Related]
30. Building a hit list for the fight against metastatic castration resistant prostate cancer. Strope JD; Price DK; Figg WD Cancer Biol Ther; 2016; 17(3):231-2. PubMed ID: 26822877 [TBL] [Abstract][Full Text] [Related]
31. WAVE1 is associated with invasiveness and growth of prostate cancer cells. Fernando HS; Sanders AJ; Kynaston HG; Jiang WG J Urol; 2008 Oct; 180(4):1515-21. PubMed ID: 18710763 [TBL] [Abstract][Full Text] [Related]
32. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492 [TBL] [Abstract][Full Text] [Related]
33. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway. Wang L; Song G; Chang X; Tan W; Pan J; Zhu X; Liu Z; Qi M; Yu J; Han B Oncogene; 2015 Sep; 34(36):4735-45. PubMed ID: 25500540 [TBL] [Abstract][Full Text] [Related]
34. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436 [TBL] [Abstract][Full Text] [Related]
35. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance. Wu X; Deng F; Li Y; Daniels G; Du X; Ren Q; Wang J; Wang LH; Yang Y; Zhang V; Zhang D; Ye F; Melamed J; Monaco ME; Lee P Oncotarget; 2015 Dec; 6(42):44849-63. PubMed ID: 26636648 [TBL] [Abstract][Full Text] [Related]
36. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer]. Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735 [TBL] [Abstract][Full Text] [Related]
37. A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice. Fokidis HB; Yieng Chin M; Ho VW; Adomat HH; Soma KK; Fazli L; Nip KM; Cox M; Krystal G; Zoubeidi A; Tomlinson Guns ES J Steroid Biochem Mol Biol; 2015 Jun; 150():35-45. PubMed ID: 25797030 [TBL] [Abstract][Full Text] [Related]
38. Prostate cancer: Genomic drivers of resistance to AR therapies. Kelsey R Nat Rev Urol; 2018 Apr; 15(4):202. PubMed ID: 29434368 [No Abstract] [Full Text] [Related]
39. Understanding cancer lineage plasticity: reversing therapeutic resistance in metastatic prostate cancer. Ellis L Pharmacogenomics; 2017 May; 18(7):597-600. PubMed ID: 28468521 [No Abstract] [Full Text] [Related]
40. Clinical and genomic features of a subtype of prostate cancer. Venkatesan P Lancet Oncol; 2018 Aug; 19(8):e394. PubMed ID: 30033225 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]